Skip to main content

 

Main menu

  • Home
  • Articles
    • Current Issue
    • Archive
    • Editorials
    • Immunology Education
    • Most Read
    • On The Horizon Collection
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Services
    • Email Alerts
    • RSS Feeds
  • More
    • AAI Disclaimer
    • Feedback
  • Other Publications
    • American Association of Immunologists
    • The Journal of Immunology

User menu

  • Log in

Search

  • Advanced search
ImmunoHorizons
  • Other Publications
    • American Association of Immunologists
    • The Journal of Immunology
  • Log in
ImmunoHorizons

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Archive
    • Editorials
    • Immunology Education
    • Most Read
    • On The Horizon Collection
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Services
    • Email Alerts
    • RSS Feeds
  • More
    • AAI Disclaimer
    • Feedback
  • Follow ImmunoHorizons on Twitter
  • Follow ImmunoHorizons on RSS
Open Access

Accelerated Blood Clearance of Lipid Nanoparticles Entails a Biphasic Humoral Response of B-1 Followed by B-2 Lymphocytes to Distinct Antigenic Moieties

Gilles Besin, Jaclyn Milton, Staci Sabnis, Rebecca Howell, Cosmin Mihai, Kristine Burke, Kerry E. Benenato, Matthew Stanton, Peter Smith, Joseph Senn and Stephen Hoge
ImmunoHorizons July 1, 2019, 3 (7) 282-293; DOI: https://doi.org/10.4049/immunohorizons.1900029
Gilles Besin
*Moderna, Inc., Cambridge, MA 02139;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jaclyn Milton
*Moderna, Inc., Cambridge, MA 02139;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Staci Sabnis
*Moderna, Inc., Cambridge, MA 02139;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rebecca Howell
*Moderna, Inc., Cambridge, MA 02139;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cosmin Mihai
*Moderna, Inc., Cambridge, MA 02139;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kristine Burke
*Moderna, Inc., Cambridge, MA 02139;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kristine Burke
Kerry E. Benenato
*Moderna, Inc., Cambridge, MA 02139;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew Stanton
†Generation Bio, Cambridge, MA 02142; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Smith
‡Alnylam, Cambridge, MA 02142
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph Senn
*Moderna, Inc., Cambridge, MA 02139;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen Hoge
*Moderna, Inc., Cambridge, MA 02139;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF + SI
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    ABC effect in WT or T cell– or B cell–deficient mice.

    (A–C) BALB/c (black, n = 3), nude (red, n = 3) or JHT mice (blue, n = 3) were injected i.v. with human Epo mRNA formulated with LNP weekly for 5 wk. (A) Human Epo protein expression in the serum was assessed by ELISA at day 1 (D1) and 24 h after the fourth injection on day 22 (D22). Significance was calculated using two-way ANOVA with Sidak posttest versus human Epo protein expression level preinjection. (B) Human Epo mRNA distribution (brown) and nuclei (blue) in the liver were visualized 24 h after the fourth injection by RNAscope in situ hybridization. Scale bar, 100 μm. (C) Anti-PEG IgM levels in serum were quantified by flow cytometric bead assay at D1 and 24 h after the fourth injection on D22. Significance was calculated using two-way ANOVA with Sidak posttest versus anti-PEG IgM level preinjection. (D) C57Bl6/J WT mice (n = 8) were injected i.v. with firefly luciferase mRNA formulated with LNP weekly (white bars) or every 2 wk (black bars). Firefly luciferase expression was measured by bioluminescence 24 h after each injection. Significance was calculated using two-way ANOVA with Sidak posttest versus luciferase activity after the first injection. (E) C57BL/6 WT mice (n = 8) were injected i.v. with firefly luciferase mRNA formulated with LNP weekly for 3 wk, followed by a fourth injection 2 wk after the third injection. Firefly luciferase expression was measured by bioluminescence 24 h after each injection. Significance was calculated using two-way ANOVA with Sidak posttest versus luciferase activity after the first injection. *p < 0.05, **p < 0.01, ***p < 0.001. n.s., not significant.

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    LNPs associate with surfaces of B cells via both PEG-dependent and PEG-independent mechanisms.

    (A) Splenocytes from C57BL/6 WT mice were incubated in the presence of medium, nonfluorescent LNP, or rhodamine-labeled LNP (LNP-PE) and analyzed by flow cytometry for fluorescence incorporation in CD19+ B cells at 24 h. Representative dotplots (left) and quantitation of percentages of PE+CD19+ cells (right) are shown. Significance was calculated using one-way ANOVA with Holm–Sidak posttest versus PBS. (B) Splenocytes from WT mice were incubated in the presence of PE-labeled LNP for 24 h and stained with DAPI (blue) to visualize the nuclei, anti–early endocytic vesicle (EEV) (green) to identify endosomal compartments, and anti-CD19 (white) to identify B cells. Cells were imaged by fluorescence microscopy to visualize LNP colocalization with either lysosomes (top) or the plasma membrane (bottom). (C) Splenocytes from WT mice were incubated in the presence of PE-labeled LNP for 24 h. Cells were analyzed by flow cytometry for PE+CD19+ B cells (left); CD86 expression (histograms) and mean fluorescence intensity (MFI) correlation (right) were calculated using a χ2 test. (D) Splenocytes from WT mice were incubated in the presence of medium, PE-labeled, PEG-containing LNP (PEG LNP-PE), or PE-labeled and PEGLess LNP (PEGLess LNP-PE) and analyzed by flow cytometry for fluorescence incorporation in CD19+ B cells at 24 h. Representative dot plots (top) and quantitation of percentages of PE+CD19+ cells (bottom) are shown. Significance was calculated using one-way ANOVA with Holm–Sidak posttest versus medium. (E and F) PEG LNP-PE or PEGLess LNP-PE were injected into WT mice i.v.. Splenocytes were harvested 6 h postinjection and either (E) LNP-PE+ fluorescence (red) signals were visualized by confocal microscopy alone (top) or colocalized with CD19+ (green) B cells (bottom) or (F) analyzed for PE fluorescence by flow cytometry. Significance was calculated using one-way ANOVA with Tukey posttest. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

  • FIGURE 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3.

    LNP PC epitopes lead to direct activation of a subset of B cells (B-1), driving ABC via natural IgM.

    (A) C57Bl6/J WT splenocytes were incubated with medium (white bars), PC-containing LNP (gray bars), or PC-containing LNP-PE (red bars) for 24 h. PE fluorescence was analyzed in the indicated B cell populations by flow cytometry. Significance was calculated using two-way ANOVA with Dunnet posttest versus medium. (B) FACS-sorted splenic CD19+CD5+ B-1 cells from WT mice were evaluated for calcium flux during stimulation with PC-containing LNP, PCLess LNP, PC-containing liposomes, or anti-IgM Ab, followed by ionomycin. (C) C57Bl6/J WT mice (n = 6 for each group) were injected i.v. with human Epo encoding mRNA formulated in PC- or PCLess-containing LNP, PBS, or nothing. Spleens were harvested 24 postinjection and splenocytes were analyzed for CD19+CD5+ B-1a cell frequency by flow cytometry. Significance was calculated using one-way ANOVA with Dunn posttest versus WT mice injected with PC LNP. (D) WT mice (n = 12) were injected i.v. weekly for 3 wk with PC LNP. Sera were collected before the first injection and 24 h after each injection and analyzed for the presence of anti-PC IgM by flow cytometric bead assay. Significance was calculated using one-way ANOVA with Dunn posttest versus preinjection serum. (E–G) WT (black symbols) or IFNAR−/− (blue symbols) mice (n = 5 for each group) were injected i.v. with human Epo encoding mRNA formulated with PC-containing LNP weekly for 5 wk (arrows on x-axis indicate the day of injection). (E) Human Epo protein expression by ELISA is shown. (F) Anti-PEG IgM and (G) anti-PC IgM levels were quantified by flow cytometric bead assay in serum 24 h postinjection. Significance was calculated using two-way ANOVA with Sidak posttest versus WT mice at each timepoint. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. n.s., not significant.

  • FIGURE 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 4.

    Removal of both B-1–mediated anti-PC natural IgM and B-2–mediated anti-PEG IgM responses abrogates ABC in mice.

    (A–E) C57Bl6/J WT or sIgM−/− mice were injected i.v. with human Epo encoding mRNA formulated with LNP weekly for 5 wk (arrows on x-axis indicate the day of injection). Human Epo protein expression was assessed in the serum of WT (open symbol) or sIgM−/− (closed symbol) mice by ELISA 6 and 24 h postinjection. Significance was calculated using two-way ANOVA with Sidak posttest versus C57Bl6/J WT mice at each timepoint. (B) Anti-PEG IgM or (C) anti-PC IgM levels were quantified by flow cytometric bead assay 24 h postinjection. Significance was calculated using one-way ANOVA with Sidak posttest versus WT mice at each timepoint. (D) Anti-PEG IgG1 (triangles) or anti-PEG IgG3 (squares) levels in serum were quantified from C57Bl6/J WT (open symbols) or sIgM−/− (closed symbols) mice by flow cytometric bead assay 24 h postinjection. Significance was calculated using one-way ANOVA with Sidak posttest versus WT mice at each timepoint. (E) Human Epo mRNA distribution (brown) and nuclei (blue) in the liver 24 h after fifth injection was visualized by in situ hybridization and hematoxylin staining, respectively. Scale bar, 100 μm. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. n.s., not significant.

  • FIGURE 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 5.

    Model of ABC for mRNA formulated in LNP.

    First injection (left): after i.v. injection with LNP, part of the injected mRNA-containing LNP is opsonized by natural anti-IgM, because of PC epitope recognition. Nonopsonized LNP are taken up by target cells and express mRNA-encoded protein. The opsonized LNP enter the spleen and are phagocytosed by APC and present the PEG lipids to B-2 cells. Phagocytosis of LNP leads to cytokine release, activating all B-1a and B-2 cells, and presentation of PEG leads to activated B-2 cells. Second and third injections (middle): because of the generation of anti-PEG Abs by B-2 cells following previous B-2 activation, more LNP are opsonized and phagocytosed in the spleen. Further, decreased amounts of nonopsonized LNP leads to decreased expression of the mRNA-encoded protein in the target cells. More than three injections (right): all LNP are opsonized and phagocytosed, and no mRNA-encoded protein expression is detectable, because of the absence of uptake of free LNP.

Additional Files

  • Figures
  • Data Supplement

    • Supplemental Figures (PDF)
PreviousNext
Back to top

In this issue

ImmunoHorizons: 3 (7)
ImmunoHorizons
Vol. 3, Issue 7
1 Jul 2019
  • Table of Contents
  • About the Cover
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about ImmunoHorizons.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Accelerated Blood Clearance of Lipid Nanoparticles Entails a Biphasic Humoral Response of B-1 Followed by B-2 Lymphocytes to Distinct Antigenic Moieties
(Your Name) has forwarded a page to you from ImmunoHorizons
(Your Name) thought you would like to see this page from the ImmunoHorizons web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Accelerated Blood Clearance of Lipid Nanoparticles Entails a Biphasic Humoral Response of B-1 Followed by B-2 Lymphocytes to Distinct Antigenic Moieties
Gilles Besin, Jaclyn Milton, Staci Sabnis, Rebecca Howell, Cosmin Mihai, Kristine Burke, Kerry E. Benenato, Matthew Stanton, Peter Smith, Joseph Senn, Stephen Hoge
ImmunoHorizons July 1, 2019, 3 (7) 282-293; DOI: 10.4049/immunohorizons.1900029

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Accelerated Blood Clearance of Lipid Nanoparticles Entails a Biphasic Humoral Response of B-1 Followed by B-2 Lymphocytes to Distinct Antigenic Moieties
Gilles Besin, Jaclyn Milton, Staci Sabnis, Rebecca Howell, Cosmin Mihai, Kristine Burke, Kerry E. Benenato, Matthew Stanton, Peter Smith, Joseph Senn, Stephen Hoge
ImmunoHorizons July 1, 2019, 3 (7) 282-293; DOI: 10.4049/immunohorizons.1900029
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Caspase-8 Blocks Receptor-Interacting Protein Kinase-1 Kinase–Independent Necroptosis during Embryogenesis
  • Systems Immunology Analyses of STAT1 Gain-of-Function Immune Phenotypes Reveal Heterogeneous Response to IL-6 and Broad Immunometabolic Roles for STAT1
  • Transcriptional and Cytotoxic Responses of Human Intestinal Organoids to IFN Types I, II, and III
Show more INNATE IMMUNITY

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive

For Authors

  • Submit a Manuscript
  • Instructions for Authors
  • About the Journal
  • Journal Policies
  • Editors

General Information

  • FAR 889
  • Privacy Policy
  • Disclaimer

Journal Services

  • Email Alerts
  • RSS Feeds

Copyright© 2022 by The American Association of Immunologists, Inc

Online ISSN 2573-7732